Abstract: A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogs, derivatives or fragments thereof, and a kit for use in such a method. After addition of the sample one or more complexes comprising `antigenic molecule of fist source!-`analyte auto antibody!-`antigenic molecule of second source! The antigenic molecule of first source is immobilized to a solid phase, the second is labeled.
Type:
Grant
Filed:
March 5, 2012
Date of Patent:
September 6, 2016
Assignee:
RSR Limited
Inventors:
Bernard Rees Smith, Jadwiga Furmaniak, Michael Powell
Abstract: The present invention provides systems and methods for analyzing the excitation spectra of fluorescent particles in a flowing stream. The system uses a white light laser and color separation optics to provide a spatially-distributed, continuous color-spectrum excitation light system that is used to illuminate a region of a flowing stream. A particle that passes through the detection region traverses the full dispersed spectrum of excitation light, and the fluorescence emissions from the particle are continuously measured as it passes through the detection region. The measured fluorescence emissions at each wavelength of excitation light, which changes through full spectrum of the excitation light as the particle passes through the detection region, provides the excitation spectrum of the particle.
Abstract: A process for detecting cells involves applying a liquid, cell-containing sample to a porous support so that the cells enter the support pores and are retained by a cell-specific binding molecule on the pore surface and, optionally after the cells are detectably labeled, performing an optical read-out by high density imaging the entire porous support volume using an optical system having an optical axis that runs in the direction of sample flow.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
August 2, 2016
Assignee:
FZMB GMBH FORSCHUNGZENTRUM FUER MEDIZINTECHNIK UND BIOTECHNOLOGIE
Abstract: A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.
Abstract: The present invention relates to a method for determining the amount of circulating CD36 protein or a fraction thereof which is present in cell-free plasma, preferably in a high molecular weight plasma fraction, such as a lipoprotein fraction selected from Low Density Lipoprotein, Intermediate Density Lipoprotein, and Very Low Density Lipoprotein using an immunological method which comprises the steps of (i) providing a plasma sample to be investigated, (ii) providing an anti-CD36 antibody, (iii) exposing the sample to be investigated to the antibody, and (iv) detecting and quantifying the amount of CD36 which binds to the antibody.
Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like.
Type:
Grant
Filed:
September 19, 2011
Date of Patent:
June 21, 2016
Assignee:
Nexus DX, Inc.
Inventors:
Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of a phosphinothricin-N-acetyl-transferase enzyme. The claimed antibodies and methods are particularly useful for identifying and quantitating the presence of phosphinothricin-N-acetyl-transferase expressed in trangenic plants.
Abstract: The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method.
Type:
Grant
Filed:
August 28, 2008
Date of Patent:
June 14, 2016
Assignees:
SHIMADZU CORPORATION, THE UNIVERSITY OF TOKYO
Abstract: A system and method to test for the presence of target molecules in a biological test sample includes test molecules, a microfluidic chip, and irradiating and detection devices. The test molecules include bio-recognition molecules conjugable with the target molecules, and the corresponding conjugates. The microfluidic chip includes sample channels and flow focusing channels adjoining the sample channels. A buffer exiting from the focusing channels directs a single-file stream of the test molecules through one of the sample channels. The irradiating device delivers radiation for absorption by the test molecules in the single-file stream. After absorption, the test molecules emit fluorescence of a distinct fluorescent spectrum for each of the conjugates. The detection device monitors identifies the presence of the conjugates by monitoring for the distinct fluorescent spectrum. Thus, the test system and method identifies the presence of the target molecules in the test sample.
Type:
Grant
Filed:
December 19, 2007
Date of Patent:
June 7, 2016
Assignee:
FIO CORPORATION
Inventors:
Qing Xiang, Warren Che Wor Chan, Jesse M. Klostranec
Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
Type:
Grant
Filed:
December 23, 2014
Date of Patent:
May 31, 2016
Assignee:
ONE LAMBDA, INC.
Inventors:
Paul Terasaki, Adam Idica, Chun-Tsan Deng
Abstract: The present invention provides labeling and capture reagents that comprise phosphorothioate oligonucleotides (PS-ODN). The PS-ODN bind to all white blood cells (leukocytes) in an indiscriminative fashion and enable the labeling, capture, or concentration of leukocytes in a manner that preserves the antigenic integrity of the cells. Methods for the use of phosphorothioate oligonucleotides are provided.
Abstract: The inventors disclose methods and systems that provide for the isolation and purification of neurons directly from heterogeneous cell cultures. The expression of various cell adhesion molecules was examined in pluripotent stem cells. Changes in the expression of one or more of these molecules correlates with the progression of cells from non-lineage committed to neural cells. Using one or more antibodies for these molecules in combination with antibodies specific for CD200 will enable one to identify and isolate neurons from a population cells.
Type:
Grant
Filed:
April 23, 2013
Date of Patent:
May 17, 2016
Assignee:
Becton, Dickinson and Company
Inventors:
Christian T. Carson, Jody Martin, Jason G. Vidal
Abstract: The present invention generally relates to systems and methods for counting biomolecules or cells. In certain embodiments, the invention provides a cell counting or biomolecule counting system including: a covered chamber having a known height and configured to hold a suspension of biomolecules or cells in a sample; at least one fluorescent light source connected to at least one fluorescent light beam narrowing device; a bright-field light source connected to a bright-field light beam narrowing device; a microscope objective; a detection device; a fluorescent filter assembly to allow only excitation light to illuminate the sample and allow only emission light from the sample to be imaged by the detection device; and a movable light shutter to block bright-field light during fluorescent detection.
Type:
Grant
Filed:
August 6, 2014
Date of Patent:
May 17, 2016
Assignee:
Nexcelom bioscience LLC
Inventors:
Bo Lin, Peter Y. Li, Jean Qiu, Timothy Smith, Todd Sobolewski, Alnoor Pirani
Abstract: There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. A method for pre-treating a glycated hemoglobin-containing sample for an immunological assay of glycated hemoglobin, the method includes treating a glycated hemoglobin-containing sample with a pre-treatment solution containing (A) guanidine or a salt thereof and (B) a nonionic surfactant and/or a nitrite.
Abstract: A method for performing an immunodiffusion assay comprising at least the following steps of: (a) preparing one or more test samples comprising an influenza virus antigen, (b) treating the test samples with at least 5% (w/v) of detergent, (c) applying the treated test samples to a gel comprising an antibody specific to the influenza virus antigen, and (d) allowing the samples to diffuse into the gel.
Type:
Grant
Filed:
September 23, 2010
Date of Patent:
May 17, 2016
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Benoit Guy Jules Baras, Valerie Audry Micheline Jacob
Abstract: The present invention pertains to a diagnostic assay for the diagnosis of an autoimmune disease. The present invention provides an improved diagnostic assay for the diagnosis of an autoimmune disease, particularly rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). In particular the invention pertains to a method of determining in a sample of a subject the presence of two or more antibodies comprising the step of determining whether an antibody is present in a sample that specifically recognizes a hnRNP-DL polypeptide or a fragment thereof or a splice variant thereof and the further step of determining whether at least one further antibody is present in the sample that specifically recognizes a at least one other hnRNP polypeptide which is not sequence homologue to said hnRNP-DL polypeptide or fragments thereof or splice variants thereof, and/or said CCP peptide and/or a polypeptide comprising at least the Fc-part of IgG, respectively.
Type:
Grant
Filed:
December 18, 2009
Date of Patent:
May 10, 2016
Assignees:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V, Charité—Universitätsmedizin Berlin
Inventors:
Zoltán Konthur, Hans Lehrach, Karl Skriner
Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
Type:
Grant
Filed:
October 18, 2013
Date of Patent:
May 3, 2016
Assignee:
KAOHSIUNG MEDICAL UNIVERSITY
Inventors:
Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
Abstract: The invention relates to an in vitro immunoassay for quantifying thrombin in a sample comprising anti-thrombin III (AT-III) and thrombin. The method comprises the following steps: contacting the sample with a small molecule that recognizes the substrate binding site of thrombin; contacting the thrombin with a thrombin specific antibody raised against a thrombin blocked in the active site; and measuring the level of bound antibody.
Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
Abstract: The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.
Type:
Grant
Filed:
October 26, 2010
Date of Patent:
April 19, 2016
Assignee:
Genentech, Inc.
Inventors:
Saloumeh Fischer, Dana L. Baker, Henry B. Lowman, Gerald R. Nakamura